Topical Bevacizumab Eyedrops for Limbal-Conjunctival Neovascularization in Impending Recurrent Pterygium

Abstract

These data suggest that off-label short-term use of topical bevacizumab may be effective to prevent recurrence in a patient with impending recurrent pterygium. We believe that this is the first known successful use of topical bevacizumab in such a patient.